1. Home
  2. ZBAI vs RLYB Comparison

ZBAI vs RLYB Comparison

Compare ZBAI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZBAI

ATIF Holdings Limited Ordinary Shares

HOLD

Current Price

$8.82

Market Cap

95.5M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$14.00

Market Cap

77.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZBAI
RLYB
Founded
2015
2018
Country
United States
United States
Employees
6
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.5M
77.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ZBAI
RLYB
Price
$8.82
$14.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.4K
281.6K
Earning Date
06-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$0.30
$0.27
52 Week High
$11.94
$15.31

Technical Indicators

Market Signals
Indicator
ZBAI
RLYB
Relative Strength Index (RSI) 61.06 82.61
Support Level $8.45 $0.54
Resistance Level $9.49 N/A
Average True Range (ATR) 0.61 0.64
MACD -0.04 0.57
Stochastic Oscillator 79.45 82.76

Price Performance

Historical Comparison
ZBAI
RLYB

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: